Inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis — overlaps with diabetes through several routes. Both Crohn’s and UC share autoimmune susceptibility with type 1 diabetes. IBD as a whole raises type 2 diabetes risk by roughly 1.3 to 1.5 times, mainly through repeated glucocorticoid courses, chronic inflammation, and inactivity during flares. Surgical resections and malabsorption further complicate glucose patterns.
The Connection Between IBD and Diabetes
- Shared autoimmune susceptibility with type 1 diabetes
- Chronic systemic inflammation drives insulin resistance
- Repeated glucocorticoid courses raise glucose and unmask diabetes
- Reduced activity during flares promotes weight gain
- Surgical resections cause malabsorption and unpredictable absorption
- Some IBD medications affect the pancreas, with implications for glucose
Diabetes Risk by IBD Subtype
| Group | Approximate Risk vs General Population |
|---|---|
| Crohn’s disease | ~1.3 to 1.5 times higher type 2 risk |
| Ulcerative colitis | ~1.3 times higher type 2 risk |
| IBD on long-term glucocorticoids | 2 to 3 times higher |
| IBD + type 1 diabetes (autoimmune cluster) | Modestly increased prevalence |
| IBD post-extensive intestinal resection | Variable, often erratic glycemia |
Steroid Strategy in IBD + Diabetes
- Prednisone — strong glucose-raising effect; minimize duration
- Budesonide — partial first-pass metabolism limits but does not eliminate effect
- IV methylprednisolone for severe flares — large transient spikes
- Topical/rectal steroids — minimal systemic absorption
- Short-term insulin often the safest treatment during high-dose courses
- Continuous glucose monitors help during taper
- Steroid-sparing strategies (biologics, immunomodulators) reduce cumulative diabetes risk
IBD Medications and Glucose Effects
- Mesalamine / 5-ASA (sulfasalazine, mesalazine, balsalazide) — glucose-neutral
- Azathioprine / 6-mercaptopurine — small pancreatitis risk; monitor amylase/lipase if abdominal pain develops
- Methotrexate — insulin-sensitizing tendency; monitor liver and kidney
- Anti-TNF (infliximab, adalimumab, certolizumab, golimumab) — glucose-neutral or modestly favorable
- Vedolizumab — glucose-neutral; gut-selective
- Ustekinumab / risankizumab — glucose-neutral
- Tofacitinib / upadacitinib / filgotinib — variable lipid effects; monitor cardiovascular risk
- Ozanimod — monitor blood pressure and lipids
- Antibiotics (ciprofloxacin, metronidazole) — fluoroquinolones can cause hypoglycemia or hyperglycemia in diabetes
Surgical Resections and Glucose
- Ileal resection — bile-acid malabsorption, B12 deficiency, fat malabsorption
- Extensive small-bowel resection — short-bowel syndrome with major nutritional challenges
- Total proctocolectomy with ileal pouch (UC) — frequent bowel movements; usually maintains carbohydrate absorption
- Stomas — dehydration risk affects diabetes drug choices (caution with SGLT2 inhibitors)
- Dumping syndrome after some surgeries — rapid glucose spike followed by reactive hypoglycemia
- Total parenteral nutrition (TPN) — careful glucose monitoring required; insulin often added to TPN bag
Nutritional Considerations
- Active flares often reduce appetite — risk of hypoglycemia for those on insulin or sulfonylureas
- Specific carbohydrate diets or low-FODMAP diets used for IBD may need diabetes adjustment
- Iron deficiency from chronic blood loss
- B12 deficiency from ileal disease or resection — affects metformin users (who already have small B12 risk)
- Vitamin D deficiency common in both diseases
- Lactose intolerance and bile-acid diarrhea may cluster
- Registered dietitian familiar with both conditions is invaluable
Cardiovascular and Bone Health
- Chronic inflammation in IBD raises cardiovascular risk modestly
- Combined with diabetes, statin therapy considered earlier
- Long-term steroids increase osteoporosis risk substantially
- DEXA scans on a regular schedule for those with significant cumulative steroid exposure
- Calcium, vitamin D, and weight-bearing exercise help
- Smoking cessation worsens Crohn’s outcomes and worsens diabetic complications
Pancreatitis and Diabetes
- Azathioprine and 6-MP carry a 3 to 7 percent risk of acute pancreatitis
- Repeated or severe pancreatitis can damage beta-cell mass, leading to pancreatogenic (type 3c) diabetes
- Symptom of new severe abdominal pain after starting these drugs warrants prompt evaluation
- Check amylase/lipase; CT or MRI if needed
- Discontinue the offending drug if pancreatitis confirmed
Vaccination and Infection
- Annual flu vaccine
- Pneumococcal vaccine series
- Hepatitis B vaccine — recommended for adults with diabetes; also for immunosuppressed IBD patients
- Shingles (recombinant zoster) vaccine
- COVID-19 boosters per current guidelines
- Live vaccines avoided during biologic therapy
Related Reading
See our overview of complications and related conditions and resources on diet and nutrition and treatment. Related autoimmune overlaps include celiac disease, psoriasis, and hepatitis.
The Bottom Line
Inflammatory bowel disease and diabetes overlap through autoimmune susceptibility, chronic inflammation, repeated glucocorticoid courses, and surgical malabsorption. IBD raises overall type 2 diabetes risk by 1.3 to 1.5 times, and the day-to-day challenge for many patients is glucose control during flares and steroid tapers. Biologic therapies are largely glucose-neutral. Surgical resections, bile-acid diarrhea, and pancreatitis risk from azathioprine all add complexity. Coordinated gastroenterology and diabetes care, with input from a dietitian familiar with both diseases, gives the best results.
